IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA

Not Applicable

Completed

• Conditions: Idiopathic Hypercalciuria; Primary Hyperoxaluria Type 1
• Interventions: Other: Urines samples; Other: Blood sample

• Registration Number: NCT02830009
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The aim of this study is to know the difference between protein profiles (multi-analyte profile) of PH1 patients, idiopathic hypercalciuria (IH) patients and PH1 patients 'siblings. Idiopathic hypercalciuria is a less severe kidney disease that PH1, which also leads to the formation of kidney stones.

The aim is to identify patterns of discriminating markers associated with primary hyperoxaluria type 1 (PH1) that will significantly improve clinical diagnosis and prognosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-05
• Primary Completion: 2013-07
• Study Completion: 2015-12
• Status Verified: 2016-07
• Study First Submitted: 2016-07-08
• Study First Submitted QC: 2016-07-08
• Study First Posted: 2016-07-12
• Last Update Submitted: 2016-07-12
• Last Update Posted: 2016-07-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Diagnosed with primary hyperoxaluria, type 1 (PH1-Cohort A); OR
• Confirmed with AGXT mutation analysis (PH1-Cohort A)
• Diagnosed with idiopathic hypercalciuria (IHC- Cohort B);
• Potential subject diagnosed with PH1 or IH and has both data entered into the registry and has matched, archived random and 24-hour urine specimens obtained prior to any treatment intervention OR is consented and enrolled into the registry or this specific study during the program;
• Healthy siblings of PH1 patients known not to have PH or any another stone disease or chronic disease will be consented and enrolled into this study through the local sites where their sibling is being treated for PH1 (this study meets the criteria for expedited review through local or central IRBs);
• Healthy non-sibling controls known not to have PH or any another stone disease or chronic disease (Healthy Control-Cohort C);
• There is no upper or lower limit to the pediatric age range of enrolling infant, children and adolescent subjects, although it is understood that accurate and complete 24-hour urine collection in very young children and infants will be problematic and will be seriously considered in advance of individual patient or healthy controls enrollment;
• eGFR (Glomerular Filtration Rate) > 60 mL/min x 1.73 m2 with PH1 and IH patient cohorts matched by mean eGFR from their initial study (or registry) enrollment/ data collection.

Read More

Exclusion Criteria

• Unwilling to provide written parent consent or adolescent assent to enroll into the International Registry or this study;
• Potential PH1, hypercalciuria, or siblings of PH1 patients with other chronic or acute illness or disease that could potentially confound proteomic results;
• Healthy intra-familial siblings unwilling to provide a blood sample for serum creatinine;
• Unwilling to provide urine specimens or permit data abstraction for the registry or this study.
• Not covered by, or having the right to, Social Security

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy volunteers	Urines samples	-
Primary Hyperoxaluria patient's siblings	Urines samples	-
Primary Hyperoxaluria patient's siblings	Blood sample	-
Primary Hyperoxaluria patient	Urines samples	-
Primary Hyperoxaluria patient	Blood sample	-
Idiopathic hypercalciuria patients	Urines samples	-
Idiopathic hypercalciuria patients	Blood sample	-
Healthy volunteers	Blood sample	-

Primary Outcome Measures

Name	Time	Method
presence of protein markers in urine	24 hours

Secondary Outcome Measures

Name	Time	Method
Presence of discriminative and robust protein markers in urine	24 hours

Trial Locations

Locations (1)

Hospices Civils de Lyon; 🇫🇷 Lyon/bron, France